Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Down 3.5 %

TRVN opened at $2.00 on Friday. The business has a 50 day moving average price of $3.72 and a two-hundred day moving average price of $6.35. Trevena has a 52 week low of $1.13 and a 52 week high of $19.23. The company has a market cap of $36.64 million, a PE ratio of -0.71 and a beta of 1.02.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($9.25) by $9.02. The company had revenue of $0.33 million for the quarter. As a group, sell-side analysts expect that Trevena will post -32.25 EPS for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.